Skip to main content

Table 2 Changes in mammographic and MRI characteristics after NAC according to subtype

From: Impact of residual microcalcifcations on prognosis after neoadjuvant chemotherapy in breast cancer patients

 

HR+ HER2− (n = 90)

HR− HER2− (n = 51)

HR+ HER2+ (n = 81)

HR− HER2+ (n = 101)

P value

Post-NAC tumor size (invasive), mm

25.0 (12.0, 50.0)

19.5 (6.3, 33.5)

13.0 (3.3, 25.0)

14.0 (3.3, 25.0)

0.004

Post-NAC tumor size (in situ), mm

30.0 (11.5, 60.0)

25.0 (7.0, 40.0)

20.0 (5.3, 46.5)

25.0 (6.0, 43.5)

0.346

Post-NAC extent of microcalcifications, mm

44.0 (27.0, 71.0)

23.5 (13.3, 35.8)

41.0 (20.5, 70.0)

48.0 (28.8, 70.3)

0.003

Changes in extent of microcalcifications

    

0.147

 No change

60 (66.7)

31 (60.8)

50 (61.7)

67 (66.3)

 

 Decreased

18 (20.0)

8 (15.7)

19 (23.5)

25 (24.8)

 

 Increased

5 (5.6)

2 (3.9)

6 (7.4)

4 (4.0)

 

 New

2 (2.2)

2 (3.9)

1 (1.2)

4 (4.0)

 

 Not specified

5 (5.6)

8 (15.7)

5 (6.2)

1 (1.0)

 

Change in morphology of microcalcifications

    

 < 0.001

 No change

46 (51.1)

18 (35.3)

35 (43.2)

51 (50.5)

 

 Change

14 (15.6)

1 (2.0)

20 (24.7)

22 (21.8)

 

 Not specified

30 (33.3)

32 (62.7)

26 (32.1)

28 (27.7)

 

Radiologic response of breast cancer on MRI

    

0.073

 CR

11 (12.2)

10 (19.6)

26 (32.1)

27 (26.7)

 

 Non-CR

78 (86.7)

41 (80.4)

54 (66.7)

73 (72.3)

 

 Not specified

1 (1.1)

0 (0.0)

1 (1.2)

1 (1.0)

 

Pathologic response of breast cancer

    

 < 0.001

 pCR

10 (11.1)

16 (31.4)

33 (40.7)

43 (42.6)

 

 Non-pCR

80 (88.9)

35 (68.6)

48 (59.3)

58 (57.4)

 
  1. Data are mean (standard deviation) or number (percentage)
  2. Abbreviations: NAC Neoadjuvant chemotherapy, HR Hormone receptor, HER2 Human epidermal growth factor receptor 2, CR Complete response, pCR Pathologic complete response